Anakinra drug retention rate and predictive factors of drug survival in systemic juvenile idiopathic arthritis and adult onset Still’s disease

Risultato della ricerca: Poster

Abstract

Introduction: Only a few studies have reported the long-term efficacy of interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult onset Still’s disease (AOSD). We herein describe Anakinra (ANA) effectiveness expressed in terms of drug retention rate (DRR) and evaluate predictive factors of drug survival in sJIA and ASOD patients.Objectives: Examine the overall DRR of ANA in sJIA and AOSD patients. Explore the influence of biologic line of treatment, and theconcomitant use of disease modifying anti-rheumatic drugs (cDMARDs) on DRR in the whole sample and stratified according to the disease thereafter; find eventual predictive factors associated with events leading to drug discontinuation. The corticosteroid (CS)- and cDMARDS-sparing effect, the impact of treatment delay on survival and the record of safety profile constituted ancillary aims.Methods: Medical records from 61 sJIA and 76 AOSD patients treated with ANA in 24 Italian tertiary referral centers were retrospectivelyreviewed.Results: The cumulative retention rate of ANA at 12-, 24-, 48- and 60-months of follow-up was 74.3%, 62.9%, 49.4% and 49.4% respectively,without any significant differences between sJIA and AOSD patients (p=0.164), and between patients treated in monotherapy compared to the subgroup co-administered with conventional cDMARDs (p=0.473). On the other hand, a significant difference in DRR was found between biologic-naive patients and those previously treated with biologic drugs (p=0.009), which persisted even after adjusting for pathology (p=0.013). In regression analysis, patients experiencing adverse events (AEs) (HR=3.029 [C.I. 1.750-5.242], p<0.0001) and those previously treated with other biotechnologic agents (HR=1.818 [C.I. 1.007-3.282], p=0.047) were associated with a higher hazard ratio of ANA discontinuation. The median treatment delay was significantly higher among patients discontinuing ANA (p<0.0001). A significant CS- (p=0.033) and cDMARDs-sparing effect (p<0.0001) was also recorded. Less than one third of our cohort developed AEs and 85% were deemed mild in nature, with 70% involving the skin.Conclusion: Our findings display an overall excellent DRR of ANA on the long run for both sJIA and AOSD that may be further optimized by closely monitoring patient’s safety issues and employing this IL-1 inhibitor as a first-line biologic as early as possible. Moreover, ANA allowed a significant drug-sparing effect while showing a good safety profile.
Lingua originaleEnglish
Numero di pagine1
Stato di pubblicazionePublished - 2019

Fingerprint

Adult-Onset Still's Disease
Interleukin 1 Receptor Antagonist Protein
Juvenile Arthritis
Survival
Pharmaceutical Preparations
Interleukin-1
Adrenal Cortex Hormones
Safety
Antirheumatic Agents
Patient Safety
Biological Products
Tertiary Care Centers
Medical Records
Therapeutics
Regression Analysis
Pathology

Cita questo

@conference{8b20d772761c4a7c8075485d6d74477c,
title = "Anakinra drug retention rate and predictive factors of drug survival in systemic juvenile idiopathic arthritis and adult onset Still’s disease",
abstract = "Introduction: Only a few studies have reported the long-term efficacy of interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult onset Still’s disease (AOSD). We herein describe Anakinra (ANA) effectiveness expressed in terms of drug retention rate (DRR) and evaluate predictive factors of drug survival in sJIA and ASOD patients.Objectives: Examine the overall DRR of ANA in sJIA and AOSD patients. Explore the influence of biologic line of treatment, and theconcomitant use of disease modifying anti-rheumatic drugs (cDMARDs) on DRR in the whole sample and stratified according to the disease thereafter; find eventual predictive factors associated with events leading to drug discontinuation. The corticosteroid (CS)- and cDMARDS-sparing effect, the impact of treatment delay on survival and the record of safety profile constituted ancillary aims.Methods: Medical records from 61 sJIA and 76 AOSD patients treated with ANA in 24 Italian tertiary referral centers were retrospectivelyreviewed.Results: The cumulative retention rate of ANA at 12-, 24-, 48- and 60-months of follow-up was 74.3{\%}, 62.9{\%}, 49.4{\%} and 49.4{\%} respectively,without any significant differences between sJIA and AOSD patients (p=0.164), and between patients treated in monotherapy compared to the subgroup co-administered with conventional cDMARDs (p=0.473). On the other hand, a significant difference in DRR was found between biologic-naive patients and those previously treated with biologic drugs (p=0.009), which persisted even after adjusting for pathology (p=0.013). In regression analysis, patients experiencing adverse events (AEs) (HR=3.029 [C.I. 1.750-5.242], p<0.0001) and those previously treated with other biotechnologic agents (HR=1.818 [C.I. 1.007-3.282], p=0.047) were associated with a higher hazard ratio of ANA discontinuation. The median treatment delay was significantly higher among patients discontinuing ANA (p<0.0001). A significant CS- (p=0.033) and cDMARDs-sparing effect (p<0.0001) was also recorded. Less than one third of our cohort developed AEs and 85{\%} were deemed mild in nature, with 70{\%} involving the skin.Conclusion: Our findings display an overall excellent DRR of ANA on the long run for both sJIA and AOSD that may be further optimized by closely monitoring patient’s safety issues and employing this IL-1 inhibitor as a first-line biologic as early as possible. Moreover, ANA allowed a significant drug-sparing effect while showing a good safety profile.",
author = "Maggio, {Maria Cristina}",
year = "2019",
language = "English",

}

TY - CONF

T1 - Anakinra drug retention rate and predictive factors of drug survival in systemic juvenile idiopathic arthritis and adult onset Still’s disease

AU - Maggio, Maria Cristina

PY - 2019

Y1 - 2019

N2 - Introduction: Only a few studies have reported the long-term efficacy of interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult onset Still’s disease (AOSD). We herein describe Anakinra (ANA) effectiveness expressed in terms of drug retention rate (DRR) and evaluate predictive factors of drug survival in sJIA and ASOD patients.Objectives: Examine the overall DRR of ANA in sJIA and AOSD patients. Explore the influence of biologic line of treatment, and theconcomitant use of disease modifying anti-rheumatic drugs (cDMARDs) on DRR in the whole sample and stratified according to the disease thereafter; find eventual predictive factors associated with events leading to drug discontinuation. The corticosteroid (CS)- and cDMARDS-sparing effect, the impact of treatment delay on survival and the record of safety profile constituted ancillary aims.Methods: Medical records from 61 sJIA and 76 AOSD patients treated with ANA in 24 Italian tertiary referral centers were retrospectivelyreviewed.Results: The cumulative retention rate of ANA at 12-, 24-, 48- and 60-months of follow-up was 74.3%, 62.9%, 49.4% and 49.4% respectively,without any significant differences between sJIA and AOSD patients (p=0.164), and between patients treated in monotherapy compared to the subgroup co-administered with conventional cDMARDs (p=0.473). On the other hand, a significant difference in DRR was found between biologic-naive patients and those previously treated with biologic drugs (p=0.009), which persisted even after adjusting for pathology (p=0.013). In regression analysis, patients experiencing adverse events (AEs) (HR=3.029 [C.I. 1.750-5.242], p<0.0001) and those previously treated with other biotechnologic agents (HR=1.818 [C.I. 1.007-3.282], p=0.047) were associated with a higher hazard ratio of ANA discontinuation. The median treatment delay was significantly higher among patients discontinuing ANA (p<0.0001). A significant CS- (p=0.033) and cDMARDs-sparing effect (p<0.0001) was also recorded. Less than one third of our cohort developed AEs and 85% were deemed mild in nature, with 70% involving the skin.Conclusion: Our findings display an overall excellent DRR of ANA on the long run for both sJIA and AOSD that may be further optimized by closely monitoring patient’s safety issues and employing this IL-1 inhibitor as a first-line biologic as early as possible. Moreover, ANA allowed a significant drug-sparing effect while showing a good safety profile.

AB - Introduction: Only a few studies have reported the long-term efficacy of interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult onset Still’s disease (AOSD). We herein describe Anakinra (ANA) effectiveness expressed in terms of drug retention rate (DRR) and evaluate predictive factors of drug survival in sJIA and ASOD patients.Objectives: Examine the overall DRR of ANA in sJIA and AOSD patients. Explore the influence of biologic line of treatment, and theconcomitant use of disease modifying anti-rheumatic drugs (cDMARDs) on DRR in the whole sample and stratified according to the disease thereafter; find eventual predictive factors associated with events leading to drug discontinuation. The corticosteroid (CS)- and cDMARDS-sparing effect, the impact of treatment delay on survival and the record of safety profile constituted ancillary aims.Methods: Medical records from 61 sJIA and 76 AOSD patients treated with ANA in 24 Italian tertiary referral centers were retrospectivelyreviewed.Results: The cumulative retention rate of ANA at 12-, 24-, 48- and 60-months of follow-up was 74.3%, 62.9%, 49.4% and 49.4% respectively,without any significant differences between sJIA and AOSD patients (p=0.164), and between patients treated in monotherapy compared to the subgroup co-administered with conventional cDMARDs (p=0.473). On the other hand, a significant difference in DRR was found between biologic-naive patients and those previously treated with biologic drugs (p=0.009), which persisted even after adjusting for pathology (p=0.013). In regression analysis, patients experiencing adverse events (AEs) (HR=3.029 [C.I. 1.750-5.242], p<0.0001) and those previously treated with other biotechnologic agents (HR=1.818 [C.I. 1.007-3.282], p=0.047) were associated with a higher hazard ratio of ANA discontinuation. The median treatment delay was significantly higher among patients discontinuing ANA (p<0.0001). A significant CS- (p=0.033) and cDMARDs-sparing effect (p<0.0001) was also recorded. Less than one third of our cohort developed AEs and 85% were deemed mild in nature, with 70% involving the skin.Conclusion: Our findings display an overall excellent DRR of ANA on the long run for both sJIA and AOSD that may be further optimized by closely monitoring patient’s safety issues and employing this IL-1 inhibitor as a first-line biologic as early as possible. Moreover, ANA allowed a significant drug-sparing effect while showing a good safety profile.

UR - http://hdl.handle.net/10447/369629

M3 - Poster

ER -